SCHEMBL841693

SCHEMBL841693

CC(=O)c1ccc(S(=O)(=O)N2CCOCC2)c(Br)c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.55
CNR1 P21554 2/20 0.55
TP53 P04637 3/20 0.55
POLB P06746 1/20 0.55
ALDH1A1 P00352 2/20 0.53
MAPT P10636 2/20 0.53
TSHR P16473 2/20 0.53
KMT2A Q03164 6/20 0.52
MEN1 O00255 3/20 0.52
MAPK1 P28482 2/20 0.52
HSD17B10 Q99714 2/20 0.52
LMNA P02545 3/20 0.51
USP2 O75604 1/20 0.51
GAA P10253 1/20 0.51
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
PKM P14618 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL840686 0.81 KMT2A (0.57) CNR2CNR1TP53POLBALDH1A1
SCHEMBL841667 0.80 LMNA (0.52) CNR2CNR1TP53POLBALDH1A1
SCHEMBL334552 0.77 ALDH1A1 (0.73) POLBALDH1A1MAPTTSHRKMT2A
SCHEMBL3949541 0.77 CNR2 (0.66) CNR2CNR1TP53ALDH1A1TSHR
SCHEMBL841442 0.75 TP53 (0.52) CNR2CNR1TP53POLBALDH1A1
SCHEMBL7321050 0.75 KMT2A (0.80) ALDH1A1MAPTTSHRKMT2AMEN1
SCHEMBL840281 0.75 ALDH1A1 (0.49) CNR2CNR1ALDH1A1TSHRKMT2A
SCHEMBL20627051 0.73 POLB (0.53) CNR2CNR1POLBALDH1A1TSHR
SCHEMBL7688673 0.73 PKM (0.62) CNR2CNR1ALDH1A1TSHRKMT2A
SCHEMBL8103599 0.73 CA2 (0.47) ALDH1A1MAPTRAB9ASMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176223-B1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY SANOFI SA (FR) 2013-01-23 EP disclosed
US-8143242-B2 Malonamide derivatives with antithrombotic activity SANOFI-AVENTIS (FR) 2012-03-27 US disclosed
US-8143242-B2 Malonamide derivatives with antithrombotic activity SANOFI-AVENTIS (FR) 2012-03-27 US disclosed
US-8143242-B2 Malonamide derivatives with antithrombotic activity SANOFI-AVENTIS (FR) 2012-03-27 US disclosed
US-20100249101-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2010-09-30 US disclosed
US-20100249101-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2010-09-30 US disclosed
US-20100249101-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2010-09-30 US disclosed
EP-2176223-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY Sanofi-Aventis (FR) 2010-04-21 EP disclosed
WO-2009007015-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249101-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY F7, F9, TFPI CNR2 1357/4885CNR1 1412/4885TP53 4884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.